1 / 16

Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy-Naïve Children

Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy-Naïve Children. PACTG 1021. Organization. Pediatric AIDS Clinical Trials Group NIAID and NICHD sponsored Drug and expertise provided by: Triangle Pharmaceuticals – Gilead Sciences Bristol Myers Squibb. Justification.

owen-strong
Download Presentation

Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy-Naïve Children

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Once-Daily Regimen of FTC, DDI, EFV in ARV Therapy-Naïve Children PACTG 1021

  2. Organization • Pediatric AIDS Clinical Trials Group • NIAID and NICHD sponsored • Drug and expertise provided by: • Triangle Pharmaceuticals – Gilead Sciences • Bristol Myers Squibb

  3. Justification • Once a day regimen improves compliance • Long half-life drugs might be more forgiving • Side effect profiles for all three drugs (FTC, ddI, EFV) individually are manageable

  4. Patient Population • ARV Naïve (allowed perinatal prophylaxis) • Three cohorts, n=37: • 90 days to <3 years (not reported at this meeting – currently enrolling) • 3 years to 12 years [21 subjects] • 13 years to 21 years [16 volunteers] • Enrollment between 9/18/2001 and 10/23/2002 • Data cut off – August 2, 2004

  5. Patient Characteristics

  6. Regimen (Once Daily) • FTC 6 mg/kg (maximum 200 mg) • ddI 240 mg/m2 (maximum 400 mg) • Oral suspension or ddI enteric coated beadlet capsules • Efavirenz – Dosing Table • Oral solution (30 mg/ml) • Capsules (50/100/200 mg)

  7. Study Design • Open label, Phase I-II • Every 4 week visits through week 96 • Intense PK at weeks 2, 8/12, and time of discontinuation • Multiple spot levels drawn • Intention to Treat Analysis • Endpoints: Safety, tolerance, proportion <50 HIV copies/ml; <400 HIV copies/ml

  8. PK Result • FTC and ddI pharmacokinetics provided anticipated AUCs • EFZ – Initial levels below anticipated for children ≤12 years receiving oral solution, so dose increased • Median AUCs (prior to adjustment)

  9. Adverse Events • 2 children discontinued before 2 weeks due to rash (one Grade 3, one Grade 2) • No subjects with laboratory abnormalities attributed to drug regimen • 1 Grade 4 hypoglycemia, 2 grade 3 CPK considered “possibly” related • 2 subjects had Grade 3 symptoms attributed to the regimen (rash; dizziness [wk1 – resolved spontaneously])

  10. Viral Response

  11. CD4 Counts and %

  12. Median Change in CD4 Ct & %

  13. Discontinuations • 10/37 Subjects discontinued treatment • 2 Rashes • 3 Virologic failure • 2 Adolescents incarcerated • 2 Subjects felt visits were inconvenient • 1 Subject moved out of the country • No Deaths or new Category C diagnoses

  14. Conclusions • Once daily Combination of FTC/ddI/EFZ well tolerated – 2 subjects with rash • Efficacy appeared to be good: • Using ITT, 72% <50 copies at week 96 • Only 3/37 discontinued because of viral failure • CD4 response was very positive: median CD4 % went from 17% to 32%

  15. Acknowledgement • Thank you to study volunteers and their families • Thank you to clinic staff of the 16 sites

  16. Ross E. McKinney, Jr, M.D. Mobeen Rathore, M.D. Chengcheng Hu, Ph.D. Paula Britto, M.S. Michael Hughes, Ph.D. Mary Elizabeth Smith, M.D. Leslie K. Serchuk, M.D. Joyce Kraimer, M.S. Alberto A. Ortiz, M.S. Linda Draper Paul Tran, R.Ph. Patricia Flynn, M.D. Ram Yogev, M.D. Stephen Spector, M.D Coleen Cunningham, M.D. Elaine Abrams, M.D. Melissa Scites, R.N. Ruth Dickover, Ph.D. Adrianna Weinberg, M.D. John Rodman, Pharm.D. H. Robert Blum, Ph.D. Gregory E. Chittick Laurie Reynolds PACTG 1021 Study Team

More Related